Disc Medicine Net Income
| IRON Stock | 55.95 15.70 21.91% |
As of the 15th of February 2026, Disc Medicine shows the Standard Deviation of 4.01, variance of 16.1, and Mean Deviation of 2.47. Disc Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Disc Medicine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Disc Medicine's valuation are provided below:We have found one hundred twenty available fundamental signals for Disc Medicine, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Disc Medicine's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 15th of February 2026, Market Cap is likely to grow to about 1.7 B. Also, Enterprise Value is likely to grow to about 1.5 B This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -98.4 M | -103.3 M | |
| Net Loss | -32.4 M | -34 M | |
| Net Loss | -98.4 M | -103.3 M | |
| Net Loss | (3.57) | (3.74) | |
| Net Income Per E B T | 0.90 | 0.80 |
Disc | Net Income | Build AI portfolio with Disc Stock |
Evaluating Disc Medicine's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Disc Medicine's fundamental strength.
Latest Disc Medicine's Net Income Growth Pattern
Below is the plot of the Net Income of Disc Medicine over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Disc Medicine financial statement analysis. It represents the amount of money remaining after all of Disc Medicine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Disc Medicine's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Disc Medicine's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (109.36 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Disc Net Income Regression Statistics
| Arithmetic Mean | (54,047,980) | |
| Coefficient Of Variation | (46.87) | |
| Mean Deviation | 20,159,735 | |
| Median | (40,837,000) | |
| Standard Deviation | 25,333,938 | |
| Sample Variance | 641.8T | |
| Range | 73.4M | |
| R-Value | (0.73) | |
| Mean Square Error | 317.6T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (3,673,091) | |
| Total Sum of Squares | 10268.9T |
Disc Net Income History
Other Fundumenentals of Disc Medicine
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Disc Medicine Net Income component correlations
Disc Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Disc Medicine is extremely important. It helps to project a fair market value of Disc Stock properly, considering its historical fundamentals such as Net Income. Since Disc Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Disc Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Disc Medicine's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.
Disc Medicine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Disc Medicine's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Disc Medicine.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Disc Medicine on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Disc Medicine or generate 0.0% return on investment in Disc Medicine over 90 days. Disc Medicine is related to or competes with Legend Biotech, Zai Lab, Tarsus Pharmaceuticals, Scholar Rock, Ascentage Pharma, Celcuity LLC, and Adaptive Biotechnologies. Disc Medicine is entity of United States More
Disc Medicine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Disc Medicine's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Disc Medicine upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 14.87 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 4.33 |
Disc Medicine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Disc Medicine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Disc Medicine's standard deviation. In reality, there are many statistical measures that can use Disc Medicine historical prices to predict the future Disc Medicine's volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (2.67) |
Disc Medicine February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (2.66) | |||
| Mean Deviation | 2.47 | |||
| Coefficient Of Variation | (771.64) | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.1 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (2.67) | |||
| Maximum Drawdown | 14.87 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 4.33 | |||
| Skewness | (2.69) | |||
| Kurtosis | 12.21 |
Disc Medicine Backtested Returns
Disc Medicine secures Sharpe Ratio (or Efficiency) of -0.16, which denotes the company had a -0.16 % return per unit of risk over the last 3 months. Disc Medicine exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Disc Medicine's Standard Deviation of 4.01, variance of 16.1, and Mean Deviation of 2.47 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.2, which means not very significant fluctuations relative to the market. As returns on the market increase, Disc Medicine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Disc Medicine is expected to be smaller as well. At this point, Disc Medicine has a negative expected return of -0.67%. Please make sure to confirm Disc Medicine's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Disc Medicine performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.56 |
Modest predictability
Disc Medicine has modest predictability. Overlapping area represents the amount of predictability between Disc Medicine time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Disc Medicine price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Disc Medicine price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 36.31 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Disc Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Disc Medicine reported net income of (109.36 Million). This is 132.04% lower than that of the Biotechnology sector and 256.12% lower than that of the Health Care industry. The net income for all United States stocks is 119.15% higher than that of the company.
Disc Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Disc Medicine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Disc Medicine could also be used in its relative valuation, which is a method of valuing Disc Medicine by comparing valuation metrics of similar companies.Disc Medicine is currently under evaluation in net income category among its peers.
Disc Medicine ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Disc Medicine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Disc Medicine's managers, analysts, and investors.Environmental | Governance | Social |
Disc Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.52 B | ||||
| Shares Outstanding | 37.75 M | ||||
| Shares Owned By Insiders | 7.88 % | ||||
| Shares Owned By Institutions | 92.21 % | ||||
| Number Of Shares Shorted | 4.1 M | ||||
| Price To Book | 3.68 X | ||||
| EBITDA | (108.27 M) | ||||
| Net Income | (109.36 M) | ||||
| Total Debt | 30 M | ||||
| Book Value Per Share | 16.38 X | ||||
| Cash Flow From Operations | (93.93 M) | ||||
| Short Ratio | 7.82 X | ||||
| Earnings Per Share | (5.37) X | ||||
| Target Price | 111.0 | ||||
| Number Of Employees | 142 | ||||
| Beta | 2.58 | ||||
| Market Capitalization | 2.11 B | ||||
| Total Asset | 496.77 M | ||||
| Retained Earnings | (298 M) | ||||
| Working Capital | 470.3 M | ||||
| Net Asset | 496.77 M |
About Disc Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Disc Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Disc Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Disc Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Disc Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against Disc Stock
| 0.78 | DRTS | Alpha Tau Medical | PairCorr |
| 0.68 | GXEA | Galapagos NV | PairCorr |
| 0.65 | EQ | Equillium | PairCorr |
| 0.63 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.62 | 6C1 | CytomX Therapeutics | PairCorr |
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.